Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1759 | Huaier Granule Wiki | 0.50 |
| drug3687 | Spironolactone 100mg Wiki | 0.50 |
| drug2077 | L-ascorbic acid Wiki | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055371 | Acute Lung Injury NIH | 0.13 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
| D055370 | Lung Injury NIH | 0.09 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 4 clinical trials
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
Description: Respiratory failure, is defined based on resource utilization of any of the following modalities: Endotracheal intubation and mechanical ventilation Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen ≥0.5) Noninvasive positive pressure ventilation or continuous positive airway pressure Extracorporeal membrane oxygenation
Measure: Subject alive and free of respiratory failure Time: Day 14Description: Type, frequency, severity, and relationship to study treatment of any TEAEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study treatment.
Measure: Occurrence of Adverse Events and Serious Adverse Events Time: 28 days after last doseDescription: Peak Plasma Concentration (Cmax)
Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax) Time: 28 days after last doseDescription: Time to Maximum Concentration (Tmax)
Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax) Time: 28 days after last doseDescription: Area under the plasma concentration versus time curve (AUC)
Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC) Time: 28 days after last doseCALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
Description: Type, frequency, severity, and relationship to study treatment of any TEAEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study treatment.
Measure: Occurrence of Adverse Events and Serious Adverse Events Time: Day 28Description: Respiratory failure, is defined based on resource utilization of any of the following modalities: Endotracheal intubation and mechanical ventilation Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen ≥0.5) Noninvasive positive pressure ventilation or continuous positive airway pressure Extracorporeal membrane oxygenation
Measure: Proportion of subjects alive and free of respiratory failure Time: Day 28Description: Plasma concentrations of acalabrutinib and ACP-5862
Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 Time: Days 3 and 7This study is being conducted to support the clinical development of acalabrutinib in participants who need treatment with proton pump inhibitors while taking acalabrutinib.
Description: Assessment of AUCinf for acalabrutinib and ACP-5862 (metabolite of acalabrutinib) following administration of capsule with and without rabeprazole.
Measure: Area under plasma concentration-time curve from time zero to infinity (AUCinf) Time: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2Description: Assessment of AUClast for acalabrutinib and ACP-5862 following administration of capsule with and without rabeprazole.
Measure: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) Time: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2Description: Assessment of Cmax for acalabrutinib and ACP-5862 following administration of capsule with and without rabeprazole.
Measure: Maximum observed plasma concentration (Cmax) Time: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2Description: Assessment of the safety and tolerability of acalabrutinib capsule when administered with COCA-COLA and rabeprazole.
Measure: Number of participants with adverse events and serious adverse events Time: From screening until Follow-up visit (Upto 5 to 6 Weeks)Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.
Description: To assess the AUC12h (area under plasma concentration-time curve from time zero to 12 hours) of the acalabrutinib NG suspension when coadministered with the PPI in participants with COVID-19
Measure: Acalabrutinib and ACP-5862 plasma PK parameter: AUC12h Time: Pre-dose and 0.5, 1, 2, 4, 6, and 12 hours post-doseDescription: To assess the AUClast (area under the plasma concentration-time curve from time zero to time of last quantifiable concentration) of the acalabrutinib NG suspension when coadministered with the PPI in participants with COVID-19
Measure: Acalabrutinib and ACP-5862 plasma PK parameter: AUClast Time: Pre-dose and 0.5, 1, 2, 4, 6, and 12 hours post-doseDescription: To assess the Cmax (maximum observed plasma concentration) of the acalabrutinib NG suspension when coadministered with the PPI in participants with COVID-19
Measure: Acalabrutinib and ACP-5862 plasma PK parameter: Cmax Time: Pre-dose and 0.5, 1, 2, 4, 6, and 12 hours post-doseDescription: To Assess Safety and tolerability of acalabrutinib suspension in participants with COVID-19 when administered in the presence of PPIs and BSC
Measure: Type, frequency, severity, and relationship to study intervention of any treatment-emergent AEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study intervention Time: From screening to 28 days (+/- 3days) after last dose of acalabrutinibDescription: To evaluate the preliminary efficacy of adding acalabrutinib suspension to BSC for treatment of participants with COVID-19
Measure: Proportion of participants alive and free of respiratory failure at Days 14 and 28 Time: Days 14 and 28Description: To evaluate the preliminary efficacy of adding acalabrutinib suspension to BSC for treatment of participants with COVID-19
Measure: Percent change from baseline in CRP at Days 3, 5, 7, 14, 28 Time: Baseline and Days 3, 5, 7, 14, 28Description: To evaluate the preliminary efficacy of adding acalabrutinib suspension to BSC for treatment of participants with COVID-19
Measure: Time to improvement- clinical improvement of ≥ 2 points(from first dose date)on a 9-point category ordinal scale Or live discharge from the hospital Or considered fit for discharge(a score of 0,1,or2 on the ordinal scale)whichever comes first,by Day 28 Time: Up to Day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports